Castration-Resistant Prostate Cancer: AUA Guideline

Cookson, Michael S.; Roth, Bruce J.; Dahm, Philipp; Engstrom, Christine; Freedland, Stephen J.; Hussain, Maha; Lin, Daniel W.; Lowrance, William T.; Murad, M. Hassan; Oh, William; Penson, David F.; Kibel, Adam S.

doi:10.1016/j.juro.2013.05.005

Cited by 218 publications

(188 citation statements)

References 41 publications

Supporting

Mentioning

182

Contrasting

Unclassified

Order By: Relevance

“…Finally, this analysis excludes the utilization and costs of chemother- Bone metastases in prostate cancer apy. Since the use of chemotherapy in patients with PC is driven by the presence of symptomatic metastatic disease, 27 it is likely that our study underestimates the total economic burden of MBD.…”

Section: Bone Metastases In Prostate Cancermentioning

confidence: 98%

Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis

Perrault¹,

Fradet²,

Lauzon³

et al. 2015

CUAJ

View full text Add to dashboard Cite

Introduction: Metastasis of prostate cancer (PC) to bone (metastatic bone disease, MBD) increases morbidity, but Canadian data are lacking on the associated healthcare resource utilization (HCRU) and costs. We quantified MBD-related HCRU and associated costs in this population, and assessed skeletal-related events (SREs), such as pathologic fracture, spinal cord compression, bone radiotherapy, and bone surgery. Methods: We conducted a retrospective, population-based cohort study using the Québec health insurance agency database. Prescription drug and medical services data were retrieved for patients with ≥1 healthcare claim in 2001 with a PC diagnosis (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] code of 185.xx). Patients with ≥2 MBDrelated claims or an SRE were compared with a matched-control group of PC patients without MBD. Patients were followed until death, loss to follow-up, or the end of available data (August 31, 2010). Costs (in 2012 Canadian dollars) were adjusted for age, year of MBD diagnosis, general health status, and baseline resource utilization. Results: Compared with controls (n = 1671), MBD patients (n = 626) had significantly higher HCRU. Adjusted mean (95% confidence interval) all-cause healthcare costs were $11 820 (7248-16 058) higher, and MBD-related costs were $3 091 (1267-4861) higher in MBD patients than in controls. Nearly 50% of MBD patients received radiotherapy within 2.5 years of their MBD diagnosis, but most exited the study without experiencing other SREs. Conclusion: MBD imposes a heavy HCRU and cost burden among patients with PC in Canada. Effective therapy is needed to reduce the clinical and economic impact of MBD in this population.

show abstract

Section: Bone Metastases In Prostate Cancermentioning

confidence: 98%

Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis

Perrault¹,

Fradet²,

Lauzon³

et al. 2015

CUAJ

View full text Add to dashboard Cite

show abstract

“…Patients with non-metastatic CRPC may only receive a chemotherapeutic agent in the context of clinical trials [4].…”

Section: Cytotoxic Agentsmentioning

confidence: 99%

The Changing Landscape in the Treatment of Metastatic Castration-Resistant Prostate Cancer: Where are we in 2017?

Pereira¹

2017

JURNOA

View full text Add to dashboard Cite

“…9 As a result, these symptomatic patients displaying detectable macroscopic metastases may be referred for systemic chemotherapy, depending on performance status outside of a clinical trial. Docetaxel is a microtubule-stabilizing taxane agent administered via intravenous infusion (75 mg/m 2 every three weeks) with daily oral prednisone (5 mg twice daily).…”

Section: Docetaxelmentioning

confidence: 99%

“…According to recent Canadian and American Urological Association guidelines, 9,10 continued observation while maintaining ADT is recommended in patients with CRPC and non-metastatic disease, as other treatments have not been shown to prolong survival in these patients. If patients are unwilling to accept observation, secondary hormonal manipulation may be considered, which includes complete androgen blockade with the administration of first-generation anti-androgens (flutamide, bicalutamide, nilutamide).…”

Section: Introductionmentioning

confidence: 99%

Contemporary agents in the management of metastatic castration-resistant prostate cancer

Kapoor

Shayegan³

et al. 2016

CUAJ

View full text Add to dashboard Cite

Docetaxel-based chemotherapy has been the standard of care for metastatic castration-resistant prostate cancer (mCRPC) since 2004. Over the past few years, there has been a significant paradigm shift in the treatment landscape of this disease. A deeper understanding of prostate cancer biology, along with the development of novel agents has created hope towards treating chemotherapy-naïve and resistant disease. Following the implementation of docetaxel as the first-line therapy for mCRPC, five novel therapies have demonstrated survival benefit in mCRPC. Cabazitaxel, abiraterone acetate, and enzalutamide are three agents recently approved for the treatment of mCRPC, having shown overall survival benefit in patients previously treated with docetaxel, while both abiraterone acetate and enzalutamide have also shown promise in the pre-docetaxel setting. Sipuleucel-T has shown overall survival benefit in asymptomatic mCRPC, while radium-223 provides survival benefit to patients with mCRPC who are symptomatic from their skeletal metastases in both docetaxel-naïve patients and post-docetaxel patients. Denosumab, an anti-RANKL antibody, has been approved for the prevention of skeletal-related events in patients with prostate cancer bone metastases. This review examines the phase 3 trials supporting the use of theses novel agents in the treatment of mCRPC. While these agents provide incremental increases in patient survival, further study to determine the best choice, combination, and/or sequencing of administration is still necessary.

show abstract

Castration-Resistant Prostate Cancer: AUA Guideline

Cited by 218 publications

References 41 publications

Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis

Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis

The Changing Landscape in the Treatment of Metastatic Castration-Resistant Prostate Cancer: Where are we in 2017?

Contemporary agents in the management of metastatic castration-resistant prostate cancer

Contact Info

Product

Resources

About